When focusing on gliomas, we found that the high expression of HIF-1α accompanied by poor prognosis, higher clinical grade, as well as the status of 1p19q codeletion and IDH mutation; These findings are consistent with previous reports regarding high HIF-1α levels and poor outcome in gliomas [32, 33]. This evidence concerns the gene IDH1 and central nervous system cancer.